Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
4Statement of changes in beneficial ownership of securities2024-02-222024-02-21
4Statement of changes in beneficial ownership of securities2024-02-212024-02-20
SC 13G/AStatement of acquisition of beneficial ownership by individuals - amended2024-02-14
8-KCurrent report2024-02-142024-02-13
10-QQuarterly report [Sections 13 or 15(d)]2024-02-132023-12-31
8-KCurrent report2024-02-092024-02-08
8-KCurrent report2024-01-192024-01-18
8-KCurrent report2024-01-162024-01-16
SC 13GStatement of acquisition of beneficial ownership by individuals2024-01-04
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
4Statement of changes in beneficial ownership of securities2023-12-262023-12-23
S-8Securities to be offered to employees in employee benefit plans2023-12-22
10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405] - amended2023-12-212023-06-30
8-KCurrent report2023-12-202023-12-19
4Statement of changes in beneficial ownership of securities2023-12-062023-12-05
8-KCurrent report2023-11-292023-11-29
8-KCurrent report2023-11-142023-11-14
10-QQuarterly report [Sections 13 or 15(d)]2023-11-142023-09-30
10-QQuarterly report [Sections 13 or 15(d)]2023-11-142023-09-30
EFFECTNotice of Effectiveness2023-11-13
424B3Prospectus [Rule 424(b)(3)]2023-11-13
S-1General form for registration of securities under the Securities Act of 19332023-11-08
  • « Previous
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 16
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*